A share price of Prime Medicine Inc [PRME] is currently trading at $4.5, up 11.39%. An important factor to consider is whether the stock is rising or falling in short-term value. The PRME shares have gain 10.02% over the last week, with a monthly amount glided 44.69%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Prime Medicine Inc [NASDAQ: PRME] stock has seen the most recent analyst activity on May 27, 2025, when Citigroup downgraded its rating to a Neutral but kept the price target unchanged to $1.50 for it. Previously, JP Morgan downgraded its rating to Neutral on May 20, 2025. On May 20, 2025, downgrade downgraded it’s rating to Neutral. JMP Securities started tracking the stock assigning a Mkt Outperform rating and suggested a price target of $10 on December 10, 2024. H.C. Wainwright initiated its recommendation with a Buy and recommended $10 as its price target on May 20, 2024. Citigroup upgraded its rating to Buy for this stock on May 16, 2024, but kept the price target unchanged to $10. In a note dated April 22, 2024, Chardan Capital Markets initiated an Buy rating and provided a target price of $17 on this stock.
Prime Medicine Inc experienced fluctuations in its stock price throughout the past year between $1.11 and $5.18. Currently, Wall Street analysts expect the stock to reach $17.25 within the next 12 months. Prime Medicine Inc [NASDAQ: PRME] shares were valued at $4.5 at the most recent close of the market. An investor can expect a potential return of 283.33% based on the average PRME price forecast.
Analyzing the PRME fundamentals
Trailing Twelve Months sales for Prime Medicine Inc [NASDAQ:PRME] were 3.85M which represents 146.02% growth. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -4.96%, Pretax Profit Margin comes in at -4.86%, and Net Profit Margin reading is -4.85%. To continue investigating profitability, this company’s Return on Assets is posted at -0.62, Equity is -1.25 and Total Capital is -0.7. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Prime Medicine Inc [NASDAQ:PRME] is 4.78. On the other hand, the Quick Ratio is 4.78, and the Cash Ratio is 2.68. Considering the valuation of this stock, the price to sales ratio is 201.62, the price to book ratio is 5.52.
Transactions by insiders
Recent insider trading involved NELSEN ROBERT, Director, that happened on Aug 01 ’25 when 3.03 million shares were purchased. 10% Owner, ARCH Venture Partners XII, LLC completed a deal on Aug 01 ’25 to buy 3.03 million shares. Meanwhile, 10% Owner ARCH Venture Partners X, LLC bought 3.03 million shares on Aug 01 ’25.
